{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood+draw+post-operative+Day+2&page=5", "query": { "intervention": "Blood draw post-operative Day 2", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 609, "total_pages": 61, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood+draw+post-operative+Day+2&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood+draw+post-operative+Day+2&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T04:33:11.148Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00924209", "title": "A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC", "Stage IIIA (N2)" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 7, "start_date": "2009-03", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2018-11-30", "last_synced_at": "2026-10-08T04:33:11.148Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00924209" }, { "nct_id": "NCT01413100", "title": "Scleroderma Treatment With Autologous Transplant (STAT) Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Scleroderma" ], "interventions": [ { "name": "Anti-Thymocyte Globulin", "type": "BIOLOGICAL" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Plerixafor", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 21, "start_date": "2011-09-15", "completion_date": "2024-09-11", "has_results": true, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-10-08T04:33:11.148Z", "location_count": 12, "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01413100" }, { "nct_id": "NCT03955978", "title": "TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometrial Cancer", "Cancer of the Endometrium" ], "interventions": [ { "name": "TSR-042", "type": "DRUG" }, { "name": "Brachytherapy", "type": "RADIATION" }, { "name": "Endometrial biopsy", "type": "PROCEDURE" }, { "name": "Blood draw for immune response", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2019-10-15", "completion_date": "2029-02-01", "has_results": false, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-10-08T04:33:11.148Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03955978" }, { "nct_id": "NCT03776487", "title": "Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage 0 Gastric Cancer AJCC v8", "Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage I Gastric Cancer AJCC v8", "Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIB Gastric Cancer AJCC v8", "Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Gastric Adenocarcinoma", "Localized Gastric Carcinoma", "Localized Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage 0 Gastric Cancer AJCC v8", "Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage I Gastric Cancer AJCC v8", "Pathologic Stage IA Gastric Cancer AJCC v8", "Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IB Gastric Cancer AJCC v8", "Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIA Gastric Cancer AJCC v8", "Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIB Gastric Cancer AJCC v8", "Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastric Cancer AJCC v8", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8" ], "interventions": [ { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2019-01-07", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-08T04:33:11.148Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03776487" }, { "nct_id": "NCT00686556", "title": "Total Marrow Irradiation for Refractory Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Myelodysplastic Syndrome", "Multiple Myeloma" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "total marrow irradiation", "type": "RADIATION" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "Granulocyte colony-stimulating factor", "type": "BIOLOGICAL" }, { "name": "HLA-matched related donor bone marrow", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "ALL", "summary": "Up to 55 Years" }, "enrollment_count": 12, "start_date": "2012-08", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-10-08T04:33:11.148Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00686556" }, { "nct_id": "NCT05364762", "title": "Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndrome", "Myeloproliferative Neoplasm", "Primary Myelofibrosis", "Secondary Myelofibrosis" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Itacitinib", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "80 Years", "sex": "ALL", "summary": "Up to 80 Years" }, "enrollment_count": 20, "start_date": "2022-11-23", "completion_date": "2027-03-25", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-08T04:33:11.148Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05364762" }, { "nct_id": "NCT00397813", "title": "Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndrome", "Essential Thrombocythemia", "Myeloproliferative Neoplasm", "Paroxysmal Nocturnal Hemoglobinuria", "Polycythemia Vera", "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase", "Primary Myelofibrosis", "Refractory Anemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Ring Sideroblasts", "Refractory Cytopenia With Multilineage Dysplasia", "Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts" ], "interventions": [ { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "50 Years to 75 Years" }, "enrollment_count": 77, "start_date": "2006-01", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2020-01-31", "last_synced_at": "2026-10-08T04:33:11.148Z", "location_count": 3, "location_summary": "Salt Lake City, Utah • Seattle, Washington", "locations": [ { "city": "Salt Lake City", "state": "Utah" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00397813" }, { "nct_id": "NCT07664176", "title": "NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma", "High Grade Gliomas", "Medulloblastoma Recurrent", "Ependymoma Recurrent", "Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS", "Brain Tumor Recurrent" ], "interventions": [ { "name": "NeuroNavigation-Guided Focused Ultrasound (NgFUS)", "type": "DEVICE" }, { "name": "Lumason", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Children's National Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "3 Years to 25 Years" }, "enrollment_count": 30, "start_date": "2026-09", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-08T04:33:11.148Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07664176" }, { "nct_id": "NCT00354172", "title": "Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "natural killer cell (NK) therapy", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "Umbilical Cord Blood Transplantation (UCBT)", "type": "PROCEDURE" }, { "name": "Total body irradiation (TBI)", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "45 Years", "sex": "ALL", "summary": "Up to 45 Years" }, "enrollment_count": 16, "start_date": "2006-02", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-10-08T04:33:11.148Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00354172" }, { "nct_id": "NCT01182519", "title": "Lung Inflammation and Lung Metastases From Breast Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "questionnaire, blood draw and urine sample", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 400, "start_date": "2010-08", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2016-07-12", "last_synced_at": "2026-10-08T04:33:11.148Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01182519" } ] }